Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study.
Snoeren N, van Hillegersberg R, Schouten SB, Bergman AM, van Werkhoven E, Dalesio O, Tollenaar RA, Verheul HM, van der Sijp J, Borel Rinkes IH, Voest EE; Hepatica study group. Snoeren N, et al. Among authors: van hillegersberg r, van werkhoven e, van der sijp j. Neoplasia. 2017 Feb;19(2):93-99. doi: 10.1016/j.neo.2016.08.010. Epub 2017 Jan 12. Neoplasia. 2017. PMID: 28088688 Free PMC article. Clinical Trial.
Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids.
van der Velden DL, Cirkel GA, Houthuijzen JM, van Werkhoven E, Roodhart JML, Daenen LGM, Kaing S, Gerrits J, Verhoeven-Duif NM, Grootscholten C, Boot H, Sessa C, Bloemendal HJ, De Vos FY, Voest EE. van der Velden DL, et al. Among authors: van werkhoven e. Cancer Chemother Pharmacol. 2018 May;81(5):911-921. doi: 10.1007/s00280-018-3563-2. Epub 2018 Mar 24. Cancer Chemother Pharmacol. 2018. PMID: 29574584 Clinical Trial.
Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience.
Meijer RP, Nieuwenhuijzen JA, Meinhardt W, Bex A, van der Poel HG, van Rhijn BW, Kerst JM, Bergman AM, van Werkhoven E, Horenblas S. Meijer RP, et al. Among authors: van rhijn bw, van werkhoven e, van der poel hg. Eur J Surg Oncol. 2013 Apr;39(4):365-71. doi: 10.1016/j.ejso.2013.01.003. Epub 2013 Jan 31. Eur J Surg Oncol. 2013. PMID: 23375648
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.
van Berge Henegouwen JM, Jebbink M, Hoes LR, van der Wijngaart H, Zeverijn LJ, van der Velden DL, Roepman P, de Leng WWJ, Jansen AML, van Werkhoven E, van der Noort V, van der Wekken AJ, de Langen AJ, Voest EE, Verheul HMW, Smit EF, Gelderblom H. van Berge Henegouwen JM, et al. Among authors: van der wekken aj, van werkhoven e, van der wijngaart h, van der velden dl, van der noort v. Eur J Cancer. 2022 Aug;171:114-123. doi: 10.1016/j.ejca.2022.05.009. Epub 2022 Jun 15. Eur J Cancer. 2022. PMID: 35716537 Free article.
The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies.
Cirkel GA, Weeber F, Bins S, Gadellaa-van Hooijdonk CG, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Ubink I, Steeghs N, de Jonge MJ, Langenberg MH, Schellens JH, Sleijfer S, Lolkema MP, Voest EE. Cirkel GA, et al. Among authors: van werkhoven e, van stralen m. Ann Oncol. 2016 Aug;27(8):1638-43. doi: 10.1093/annonc/mdw223. Epub 2016 May 27. Ann Oncol. 2016. PMID: 27234642 Free article. Clinical Trial.
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, Schilsky RL, de Leng WWJ, Huitema ADR, Nuijen B, Nederlof PM, van Herpen CML, de Groot DJA, Devriese LA, Hoeben A, de Jonge MJA, Chalabi M, Smit EF, de Langen AJ, Mehra N, Labots M, Kapiteijn E, Sleijfer S, Cuppen E, Verheul HMW, Gelderblom H, Voest EE. van der Velden DL, et al. Among authors: van berge henegouwen jm, van werkhoven e, van der wijngaart h, van herpen cml. Nature. 2019 Oct;574(7776):127-131. doi: 10.1038/s41586-019-1600-x. Epub 2019 Sep 30. Nature. 2019. PMID: 31570881 Clinical Trial.
Prospective experimental treatment of colorectal cancer patients based on organoid drug responses.
Ooft SN, Weeber F, Schipper L, Dijkstra KK, McLean CM, Kaing S, van de Haar J, Prevoo W, van Werkhoven E, Snaebjornsson P, Hoes LR, Chalabi M, van der Velden D, van Leerdam M, Boot H, Grootscholten C, Huitema ADR, Bloemendal HJ, Cuppen E, Voest EE. Ooft SN, et al. Among authors: van leerdam m, van werkhoven e, van der velden d, van de haar j. ESMO Open. 2021 Jun;6(3):100103. doi: 10.1016/j.esmoop.2021.100103. Epub 2021 Apr 19. ESMO Open. 2021. PMID: 33887686 Free PMC article.
Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.
van Waalwijk van Doorn-Khosrovani SB, Pisters-van Roy A, van Saase L, van der Graaff M, Gijzen J, Sleijfer S, Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, van der Velden DL, van Werkhoven E, Retel VP, van Harten WH, Huitema ADR, Timmers L, Gelderblom H, Verheul HMW, Voest EE. van Waalwijk van Doorn-Khosrovani SB, et al. Among authors: van harten wh, van berge henegouwen jm, van werkhoven e, van der wijngaart h, van der velden dl, van saase l, van der graaff m. Ann Oncol. 2019 May 1;30(5):663-665. doi: 10.1093/annonc/mdz119. Ann Oncol. 2019. PMID: 31038154 Free article. No abstract available.
Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period.
Bosma SC, van der Leij F, van Werkhoven E, Bartelink H, Wesseling J, Linn S, Rutgers EJ, van de Vijver MJ, Elkhuizen PH. Bosma SC, et al. Among authors: van werkhoven e, van der leij f, van de vijver mj. Breast Cancer Res Treat. 2016 Apr;156(2):391-400. doi: 10.1007/s10549-016-3732-0. Epub 2016 Mar 23. Breast Cancer Res Treat. 2016. PMID: 27008183
Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).
van Rossum AGJ, Kok M, van Werkhoven E, Opdam M, Mandjes IAM, van Leeuwen-Stok AE, van Tinteren H, Imholz ALT, Portielje JEA, Bos MMEM, van Bochove A, Wesseling J, Rutgers EJ, Linn SC, Oosterkamp HM; MATADOR Trialists' Group. van Rossum AGJ, et al. Among authors: van bochove a, van werkhoven e, van tinteren h, van leeuwen stok ae. Eur J Cancer. 2018 Oct;102:40-48. doi: 10.1016/j.ejca.2018.07.013. Eur J Cancer. 2018. PMID: 30125761 Free article. Clinical Trial.
139 results